We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Boehringer Ingelheim Selects Genedata Biologics as Antibody Discovery Workflow Platform

News   Feb 19, 2015

 
Boehringer Ingelheim Selects Genedata Biologics as Antibody Discovery Workflow Platform
 
 
Advertisement
 

RELATED ARTICLES

First Comprehensive Review of COVID-19's Effects Outside the Lung Published

News

The first extensive review of COVID-19's effects on all affected organs outside the lungs has been published in Nature Medicine, by researchers from Columbia University.

READ MORE

SARS-CoV-2 Immunity Rapidly Declines Within Months of Infection

News

A recent preprint study indicates that there is a rapid decline in the levels of SARS-CoV-2 neutralizing antibodies during the weeks following initial infection. This raises questions over the potential for re-infection, the effectiveness that may be expected from vaccination and the viable window for antibody testing in disease surveillance.

READ MORE

Why Lopinavir and Hydroxychloroquine Are Ineffective in COVID-19 Patients

News

A research group has discovered that the concentration of lopinavir and hydroxychloroquine in the lungs of COVID-19 patients is not sufficient to fight the virus.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE